Tuesday, November 7, 2017
- 9:00AM-11:00AM
-
Abstract Number: 1993
Are MRI-Detected Erosions Specific for RA? a Large Explorative Cross-Sectional Study
Imaging of Rheumatic Diseases Poster II- 9:00AM-11:00AM
-
Abstract Number: 2351
Are Sedentary Behavior and Reduced Physical Activity Associated with Long-Term Cardiovascular Risk in Individuals with Rheumatoid Arthritis?
Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 2500
Are Work Outcomes Improved in Axial Spondyloarthritis (axSpA) Patients with Biologic Therapy? Results from the British Society for Rheumatology Register
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 2089
Arhalofenate Acid Inhibits Urate Crystal-Induced Inflammatory Responses through Activation of AMP-Activated Protein Kinase (AMPK) Signaling
Metabolic and Crystal Arthropathies Poster II- 9:00AM-11:00AM
-
Abstract Number: 2355
Arterial Wave Reflection and Subclinical Atherosclerosis in Rheumatoid Arthritis
Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 2257
Assessing the Impact of a Digital Health Coaching Program for Patients with Rheumatoid Arthritis
Patient Outcomes, Preferences, and Attitudes Poster III- 9:00AM-11:00AM
-
Abstract Number: 2301
Assessing the Utility and Impact of Musculoskeletal Ultrasound in a Large Pediatric Rheumatology Clinic
Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster III: Juvenile Arthritis- 9:00AM-11:00AM
-
Abstract Number: 2727
Assessment of Damage and Prognosis in Patients with Adult IgA Vasculitis: Retrospective Multicentered Cohort Study
Vasculitis Poster III: Other Vasculitis Syndromes- 9:00AM-11:00AM
-
Abstract Number: 2476
Assessment of Dose Dependent Effects of Vobarilizumab, an Anti-IL6 Receptor (IL-6R) Nanobody®, on Systemic Biomarkers in Patients with Moderate-to-Severe Rheumatoid Arthritis (RA): Results of Two Phase 2b Studies
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars- 9:00AM-11:00AM
-
Abstract Number: 2011
Assessment of Methods to Quantitatively Evaluate Global Synovitis Activity with FDG-PET/CT
Imaging of Rheumatic Diseases Poster II- 9:00AM-11:00AM
-
Abstract Number: 2413
Assessment of the Most Distal Sensory Nerves in Patients with Rheumatoid Arthritis with Normal Value of Standard Nerve Conduction Studies
Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 2361
Associated Factors of Hypertension and Hyperglycemia Related to Steroid Pulse in Autoimmune Diseases
Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 1971
Association between Genetic Variants and the Presence of Rheumatoid Arthritis-Related Autoimmunity and Progression to Classified Rheumatoid Arthritis in an at-Risk Population
Epidemiology and Public Health Poster III: Rheumatic Disease Risk and Outcomes- 9:00AM-11:00AM
-
Abstract Number: 2465
Association between Methotrexate Use and Effects of Treatment with a Second Biologic Agent in Rheumatoid Arthritis: A Multiple Imputation Approach